Cellebrite DI (NASDAQ:CLBT) Price Target Raised to $23.00 at Lake Street Capital

Cellebrite DI (NASDAQ:CLBTFree Report) had its price target upped by Lake Street Capital from $22.00 to $23.00 in a research note published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, November 7th. Bank of America increased their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Needham & Company LLC lifted their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Get Our Latest Research Report on Cellebrite DI

Cellebrite DI Price Performance

NASDAQ CLBT traded down $0.83 during mid-day trading on Thursday, reaching $18.45. 2,163,011 shares of the stock were exchanged, compared to its average volume of 1,649,538. The stock has a market cap of $4.42 billion, a P/E ratio of -24.28, a P/E/G ratio of 3.16 and a beta of 1.28. The stock has a 50 day simple moving average of $17.81 and a 200-day simple moving average of $16.70. Cellebrite DI has a one year low of $13.10 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $126.03 million for the quarter, compared to analyst estimates of $122.98 million. During the same period in the prior year, the business earned $0.14 EPS. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Several hedge funds have recently modified their holdings of CLBT. Y Intercept Hong Kong Ltd bought a new position in Cellebrite DI in the 2nd quarter valued at $657,000. Harbor Capital Advisors Inc. increased its stake in shares of Cellebrite DI by 19.4% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 145,692 shares of the company’s stock worth $2,331,000 after purchasing an additional 23,638 shares during the last quarter. MQS Management LLC purchased a new position in Cellebrite DI in the second quarter valued at approximately $256,000. Venturi Wealth Management LLC bought a new position in Cellebrite DI during the second quarter valued at $224,000. Finally, Nordea Investment Management AB raised its stake in shares of Cellebrite DI by 2.1% in the second quarter. Nordea Investment Management AB now owns 174,734 shares of the company’s stock valued at $2,766,000 after buying an additional 3,644 shares during the period. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Recommended Stories

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.